Avalo Therapeutics (NASDAQ:AVTX) Reaches New 1-Year High Following Analyst Upgrade

Key Points

• Shares hit a new 52-week high after Wedbush raised its price target from $29 to $40 and kept an outperform rating; AVTX traded as high as $23.71 (last $19.91) on a volume of 7,937,360 shares.
• Analyst sentiment is broadly positive — MarketBeat shows a "Moderate Buy" consensus with an average price target of $46.71, and several firms have buy/outperform targets up to $50.
• Notable insider selling amid heavy institutional ownership — insiders sold 63,015 shares (~$987,326) in the last 90 days (including a recent CFO sale), while institutional investors hold about 87.06% and insiders own 4.46%.

Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) reached a new 52-week high on Wednesday after Wedbush raised their price target on the stock from $29.00 to $40.00. Wedbush currently has an outperform rating on the stock. Avalo Therapeutics traded as high as $23.71 and last traded at $19.9110, with a volume of 7937360 shares changing hands. The stock had previously closed at $16.26.

Several other equities research analysts have also weighed in on AVTX. Citigroup reiterated an "outperform" rating on shares of Avalo Therapeutics in a research note on Wednesday. Weiss Ratings reiterated a "sell (d-)" rating on shares of Avalo Therapeutics in a research note on Wednesday, April 8th. HC Wainwright upped their price objective on Avalo Therapeutics from $25.00 to $40.00 and gave the company a "buy" rating in a research note on Wednesday, March 25th. Guggenheim started coverage on Avalo Therapeutics in a research note on Monday, February 2nd. They issued a "buy" rating and a $50.00 price objective on the stock. Finally, Wolfe Research started coverage on Avalo Therapeutics in a research note on Thursday, April 9th. They issued an "outperform" rating and a $48.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Avalo Therapeutics has an average rating of "Moderate Buy" and an average price target of $46.71.

Insider Buying and Selling

In related news, CFO Christopher Ryan Sullivan sold 8,457 shares of the stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $13.23, for a total transaction of $111,886.11. Following the sale, the chief financial officer directly owned 423 shares in the company, valued at $5,596.29. This represents a 95.24% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mittie Doyle sold 3,970 shares of the stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $18.01, for a total value of $71,499.70. Following the sale, the insider owned 3,622 shares in the company, valued at approximately $65,232.22. This trade represents a 52.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 63,015 shares of company stock worth $987,326. 4.46% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Avalo Therapeutics

Large investors have recently bought and sold shares of the business. Patient Square Capital LP bought a new stake in Avalo Therapeutics during the 3rd quarter worth approximately $1,271,000. Cantor Fitzgerald L. P. bought a new stake in Avalo Therapeutics during the 3rd quarter worth approximately $1,083,000. Boothbay Fund Management LLC grew its position in Avalo Therapeutics by 1,916.6% during the 3rd quarter. Boothbay Fund Management LLC now owns 228,297 shares of the company's stock worth $2,902,000 after acquiring an additional 216,976 shares during the last quarter. Ally Bridge Group NY LLC bought a new stake in Avalo Therapeutics during the 3rd quarter worth approximately $2,264,000. Finally, Boxer Capital Management LLC bought a new stake in Avalo Therapeutics during the 3rd quarter worth approximately $1,589,000. 87.06% of the stock is currently owned by institutional investors.

Avalo Therapeutics Stock Performance

The stock has a 50-day moving average of $15.33 and a 200 day moving average of $16.24. The firm has a market capitalization of $562.89 million, a P/E ratio of -3.62 and a beta of 0.78.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last posted its quarterly earnings data on Monday, March 23rd. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.54) by $1.17. The firm had revenue of $0.06 million for the quarter, compared to analyst estimates of ($0.21) million. On average, equities analysts predict that Avalo Therapeutics, Inc. will post -4.04 EPS for the current year.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company's proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.